[Exploring all-cause community-acquired pneumonia as an endpoint for adult pneumococcal vaccine clinical research].

Authors

M Lyu, S Bai, J Wu

Published in

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. Volume 60. Issue 9. Pages 1529-1537. Sep 06, 2026.

Abstract

Community-acquired pneumonia (CAP) represents a major global public health problem, characterized by high morbidity and mortality, particularly among the elderly and patients with chronic diseases. As Streptococcus pneumoniae is one of the primary pathogens causing CAP, the development and evaluation of pneumococcal vaccines are of paramount clinical importance. Selecting appropriate endpoints is critical for scientifically assessing a vaccine's protective efficacy in trials. Traditionally, invasive pneumococcal disease (IPD) has been widely used as a primary endpoint. However, its low incidence and the consequent requirement for large sample sizes have constrained its application in adult vaccine evaluation. Consequently, all-cause CAP has emerged in recent years as an alternative endpoint that is both broader in scope and more clinically relevant. This paper reviews the scientific rationale, advantages, and challenges of using all-cause CAP as an endpoint in adult pneumococcal vaccine trials. We propose a multi-dimensional framework integrating vaccine efficacy (VE), vaccine-preventable disease incidence (VPDI), and the number needed to vaccinate (NNV). This framework enables differentiated assessments across regions with varying diagnostic capacities, thereby advancing China's vaccine research and evaluation systems.

PMID:
42736158
Bibliographic data and abstract were imported from PubMed on 15 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.